House committee debates MOUD bill: members split over scope, data and private contractor role

Committee members spent the bulk of the April 24 meeting on a bill that would codify and clarify the Department of Corrections’ medication for opioid use disorder (MOUD) practices inside correctional facilities and at reentry.

Lede and what it would do

Committee members heard that the MOUD program was established in corrections in about 2017–2018 and that this bill primarily cleans up statutory language and codifies practices the Department of Corrections (DOC) and its contractor already perform: continuing MOUD during incarceration, arranging appointments with community “hubs” for reentry, and ensuring detainees leave with enough medication to bridge until a community appointment. The sponsor said the bill does not create the MOUD program or repeal it; it “tidies” statutory language and allows DOC to use newer delivery forms such as injectable formulations if appropriations permit.

Why it matters

Members framed the bill as a continuity-of-care measure for people in custody: supporters said consistent treatment reduces overdose and supports reentry, while opponents said the policy risks perpetuating addiction, may increase costs, and raises concerns about relying on a private contractor for care.

Key points of debate

Scope and practice: Several members repeatedly stated that the bill “does not change current practice” but clarifies and modernizes language, including an allowance for injectables if DOC requests and the Legislature funds them. One committee member said the bill should be on the floor “as is” because it primarily codifies current practice and provides guardrails for contractors.

Data and evaluation: Multiple members urged better data collection to show whether people who leave custody continue MOUD treatment in the community and whether reentry outcomes improve. Committee staff agreed to press DOC and relevant contractors for data on post-release medication refills and continuity measures.

Private contractor and costs: Members raised concerns about Wellpath, the DOC contractor named in testimony, and whether profit incentives could affect prescribing or reporting. Witnesses and members asserted that Wellpath is paid on a flat contract rate, not per pill, and that contract language includes reimbursement formulas and limits. Members noted injectables would increase costs and would require appropriations; DOC has requested the statutory flexibility to use injectables but acknowledged cost constraints.

Clinical testimony and conflicted views: Members said testimony from clinicians and people with lived experience had influenced their views. Several members emphasized that opioid use disorder is a medical condition and that medication is an evidence-based component of treatment; other members expressed philosophical opposition to medication-centric approaches and worried about diversion and community capacity for follow-up treatment.

Progress in other chambers: Scott Moore of the fiscal office told the committee that the Senate institutions committee had voted the bill out of committee at 03:10 with a 5-0-0 tally (committee-level approval). The chair clarified that even if the bill moves out of committee here, it likely will not become law this year and that circulation of a side-by-side with the Senate version is scheduled.

What the bill would not change

Members repeatedly noted: the MOUD program has existed several years; the bill does not repeal or eliminate existing programs; last year the committee added a requirement for DOC or its contractor to arrange a follow-up appointment with a community hub before release and to provide bridging medication sufficient to reach that appointment.

Next steps

Committee staff will receive another draft from bill drafter Katie at the next meeting; staff also plan to follow up with DOC and contractor representatives to secure requested data on post-release MOUD continuation. The committee signaled it wants to move a cleaned-up draft but remains split on whether the bill should be expanded to include stronger data or structural changes such as changing the contractor model.

Ending

The committee scheduled further drafts and a side-by-side comparison with the Senate version and asked fiscal staff to brief members on timing; members were warned to expect “calendar math” and possible late-session scheduling.